Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sud ...
Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sud ...
Study of the value of early treatment in patients with sudden blindness
Study of the value of early treatment with an endothelin inhibitor (Bosentan) in patients with sudden blindness secondary to giant cell arteritis - CECIBO Study of the value of early treatment with an endothelin inhibitor (Bosentan) in patients with sudde ...
Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...